Nuclear Sclerosis, also known as Lenticular Sclerosis, occurs in older pets and causes the eyes to look cloudy. Although these changes may look scary, this is actually a normal ageing change.
The lens of the eye gives the eye the ability to focus on objects by transmitting light to the retina at the back of the eye. It is made up of tissue fibres that are normally clear. But as pets get older, more fibres come together in the lens and as the fibres become denser, the lens becomes more opaque, giving the eye a blue-grey sheen.
Who is affected?
Any aging pet can be affected by Nuclear Sclerosis but according to PetSure data from the 2020 calendar year it was most prevalent in the following breeds:
|Australian Silky Terrier||0.19%|
|Fox terrier Smooth||0.14%|
|German Short-haired Pointer||0.04%|
Prevalence = Total number of unique claiming pets / total number of insured pets across 12-month period. Excludes breeds with less than 500 active pet insurance policies.
Signs of Nuclear Sclerosis
Often the first sign of Nuclear Sclerosis is a blueish or cloudy haze in both eyes. It might look like it comes and goes but this can be due to the lens changing size in different light. It can be easy to mix up Nuclear sclerosis with cataracts, but your Vet will be able to examine your pets eyes and advise you.
Generally, pets with Nuclear Sclerosis don’t have significant vision loss, so if you think your pet might be having problems seeing, get in touch with your Vet straight away as something more serious could be going on.
Management of Nuclear Sclerosis
Generally, there is no specific treatment for Nuclear Sclerosis, and management is about having regular check-ups of the eyes to make sure that no other problems are developing behind the scenes, such as cataracts.
How much does it cost to treat Nuclear Sclerosis?
PetSure claims data from the 2020 calendar year show the average single treatment for Nuclear Sclerosis was $134, and the highest single treatment $396.
Disclaimer: Reimbursement for these claims would be subject to limits, such as annual benefit limits or sub-limits, benefit percentage, applicable waiting periods and any applicable excess. Cover is subject to the policy terms and conditions. You should consider the relevant Product Disclosure Statement or policy wording available from the relevant provider.
- Davis, R, 2021, Cataract, VINCYCLOPEDIA OF DISEASES, accessed on 8/7/21
- Clode, A, Differentiating Nuclear Sclerosis From Cataracts, Clinician’s Brief, 2016, accessed on 08/07/2021
Petinsurance.com.au is general insurance issued by the insurer The Hollard Insurance Company Pty Ltd (ABN 78 090 584 473; AFSL 241436) (Hollard); is promoted and distributed by Pet Insurance Pty Ltd (ABN 38 607 160 930; AR 1234944) (PIPL) and PIPL’s authorised distribution partners (including Pet Culture Group Pty Limited ABN: 69 644 613 098; AR 001284860) (PetCulture) and administered by PetSure (Australia) Pty Ltd (ABN 95 075 949 923; AFSL 420183) (PetSure). PIPL and PetCulture are authorised representatives of PetSure. Any advice provided is general only, has been prepared without taking into account your objectives, financial situation or needs and may not be right for you. Consequently, before acting on this information, you should consider the appropriateness of this information having regard to your objectives, financial situation and needs. You should obtain and consider the product disclosure statement (PDS) in deciding whether to acquire or continue to hold, Petinsurance.com.au Pet Insurance.